Novartis makes protein degrader play, inking deal with new British startup to access fruits...

[cafead]

via The search for an edge in the hot protein degrader space has led Novartis to Dunad Therapeutics. By putting up $24 million and committing to $1.3 billion in biobucks, Novartis has secured the chance to option candidates against up to four targets worked on by its new partner.

article source